NCT02889900 2022-03-08
CONCERTO
AstraZeneca
Phase 2 Completed
Clinical Trials
22 trialsNCT00384176 2017-04-14
HORIZON III
AstraZeneca
Phase 2/3 Completed
NCT00423332 2017-02-02
Cediranib (AZD2171, RECENTIN™) in Metastatic or Recurrent Renal Cell Carcinoma
AstraZeneca
Phase 2 Completed
NCT00399035 2016-12-28
HORIZON II
AstraZeneca
Phase 3 Completed
NCT00777153 2016-12-28
REGAL
AstraZeneca
Phase 3 Completed
NCT00454805 2016-08-03
AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer.
AstraZeneca
Phase 2 Completed
NCT00621725 2014-07-15
Phase 1 PK Study of Cediranib in Single and Multiple Doses in Hepatically Impaired Patients With Solid Tumours
AstraZeneca
Phase 1 Completed
NCT00494221 2014-03-27
A Phase I/II Study of Cediranib (AZD2171) in Japanese Metastatic Colorectal Cancer Patients in Combination With FOLFOX
AstraZeneca
Phase 1/2 Completed
NCT00243347 2013-10-17
The Effects of AZD2171 in Patients With Non-Small Cell Lung Cancer or Head & Neck Cancer
AstraZeneca
Phase 1 Completed
NCT00621361 2012-12-17
Phase I Safety and Tolerability Study of Cediranib (RECENTIN™, AZD2171) in Combination With Chemo in First Line Lung Cancer Patients
AstraZeneca
Phase 1 Completed
NCT00306891 2012-11-01
Effect of Food Upon Pharmacokinetics of Single Oral Dose of Cediranib (AZD2171, Recentin™)
AstraZeneca
Phase 2 Completed
NCT00278889 2012-10-24
HORIZON I
AstraZeneca
Phase 2 Completed
NCT00385203 2012-07-16
The Biological Activity of Cediranib (AZD2171) in Gastro-Intestinal Stromal Tumours(GIST).
AstraZeneca
Phase 2 Completed
NCT00748891 2011-07-01
DCE CT/MRI Scanning Study in Patients With Solid Tumours (AstraZeneca and Royal Marsden Hospital Imaging Study)
AstraZeneca
Phase 1 Completed
NCT00981721 2011-06-20
A Study to Determine the Pharmacokinetics of Cediranib in Chinese Patients With Advanced Solid Malignancies
AstraZeneca
Phase 1 Completed
NCT00960349 2011-06-14
Study of Cediranib Plus Cisplatin Plus Capecitabine/S-1 in Japanese Gastric Cancer Patients
AstraZeneca
Phase 1 Completed
NCT00750425 2011-03-10
Phase 1 Study of the Effect of Ketoconazole on the PK of Multiple Doses of Cediranib in Patients With Solid Tumours
AstraZeneca
Phase 1 Completed
NCT00502385 2011-01-21
Phase I AZD2171 in Patients With Relapsed or Refractory AML and Elderly Patients With DeNovo or Secondary AML
AstraZeneca
Phase 1 Completed
NCT00475956 2010-04-15
Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours
AstraZeneca
Phase 1 Completed
NCT00503204 2009-11-25
Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain Tumour
AstraZeneca
Phase 1 Completed
NCT00502060 2009-05-14
Phase I Study of AZD2171 co-Administered With Fixed Multiple Oral Doses of ZD1839 in Patients With Advanced Cancer
AstraZeneca
Phase 1 Completed
NCT00503412 2009-01-19
Phase I Orally Administered 14C-AZD2171 in Patients With Solid Metastatic Tumors
AstraZeneca
Phase 1 Completed